Effects of a Novel Antihyperlipidemic Agent, S-2E, on the Blood Lipid Abnormalities in Homozygous WHHL Rabbits

Metabolism: Clinical and Experimental

Volumn 53, Issue 5, 2004, Pages 680-685

  Ohmori, Koichi ^a   Yamada, H ^a   Yasuda, A ^a   Yamamoto, A ^a   Matsuura, N ^a   Kiniwa, M ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (4 TERT BUTYLPHENYL) 2 OXO 4 PYRROLIDINYL]METHOXYBENZOIC ACID; ANTILIPEMIC AGENT; BENZOIC ACID DERIVATIVE; CHOLESTEROL; FATTY ACID; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; S 2E; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY ACID SYNTHESIS; HOMOZYGOSITY; HYPERLIPIDEMIA; HYPOLIPIDEMIC ACTIVITY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 2342531091     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.11.024     Document Type: Article

References (33)

1. McKenney JM: Pharmacotherapy of dyslipidemia. Cardiovasc Drugs Ther 15:413-422, 2001
2. Ballantyne CM: Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 82:3Q-12Q, 1998
3. Ucar M, Mjorndal T, Dahlqvist R: HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 22:441-457, 2000
4. Wetterau JR, Aggerbeck LP, Bouma ME, et al: Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258:999-1001, 1992
5. Olofsson SO, Aap L, Boren J: The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol 10:341-346, 1999
6. Wetterau JR, Gregg RE, Harrity TW, et al: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282:751-754, 1998
7. Shiomi M, Ito T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 431:127-131, 2001
8. Tanzawa K, Shimada Y, Kuroda M, et al: WHHL rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. FEBS Lett 118:81-84, 1980
9. Kita T, Brown MS, Watanabe Y, et al: Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbits, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA 78:2268-2272, 1981
10. Ohno T, Yano S, Yamada H, et al: Synthesis of the optical isomers of 4-[1-(4-tert-butylphenyl)-2-oxo-4-pyrrolidine-4-yl]methyl-oxybenzoic acids (S-2) and their biological evaluation as antilipidemic agent. Chem Pharm Bull 47:1549-1554, 1999
11. Ohmori K, Yamada H, Yasuda A, et al: Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Phamacol 471:69-76, 2003
12. Hatch FT, Lees RS: Practical method for plasma lipoprotein analysis. Adv Lipid Res 6:1-68, 1968
13. Bilheimer DW, Grundy SM, Brown MS, et al: Mevilonin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia. Proc Natl Acad Sci USA 90:80-84, 1983
14. Reiher E, Rudling M, Stahhlberg D, et al: Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 332:224-228, 1990
15. Ginsberg HN, Le NA, Short MP: Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 80:1692-1697, 1987
16. Arad Y, Ramakrishnan R, Ginsberg HN: Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications of the pathophysiology of apoB production. J Lipid Res 31:567-582, 1990
17. Bakker-Arkema RD-G, Davidson MH, Goldstein RJ, et al: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275:128-133, 1996
18. Hiyoshi H, Yanagimachi M, Ito M, et al: Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur J Pharmacol 23:345-352, 2001
19. Tsujita Y, Kuroda M, Shimada Y, et al: CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 877:50-60, 1986
20. Watanabe Y, Ito T, Saeki M, et al: Hypolipidemic effects of CS-500 (ML-236B) in WHHL rabbits, a heritable animal model of hyperlipidemia. Atherosclerosis 38:27-81, 1981
21. Khachadurian AK, Shimamura T, Rozovski SJ, et al: Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits. Jpn Heart J 32:675-685, 1991
22. Shiomi M, Ito T: Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits. Metabolism 43:559-564, 1994
23. Shiomi M, Ito T: Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 126:961-968, 1999
24. Shiomi M, Ito T, Tsukada T, et al: Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 142:345-353, 1999
25. Staels B, Dallongeville J, Aurwerx J, et al: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093, 1998
26. Linton MF, Fazio S: Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Curr Atheroscler Rep 2:29-35, 2000
27. Dana SL, Hoener PA, Bilakovs JM, et al: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in Zucker diabetic fatty rats. Metabolism 50:963-971, 2001
28. Kwiterovich PO Jr: The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q-21Q, 1998
29. Bray GA: The Zucker fatty rat: A review. Fed Proc 36:148-153, 1977
30. Cartwright IJ, Plonnè D, Higgins JA: Intracellular events in the assembly of chylomicrons in rabbit enterocytes. J Lipid Res 41:1728-1739, 2000
31. Levy E, Beaulieu J-F, Delvin E, et al: Human crypt intestinal epithelial cells are capable of lipid production, apolipoprotein synthesis, and lipoprotein assembly. J Lipid Res 41:12-22, 2000
32. Hara H, Haga S, Aoyama Y, et al: Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine. J Nutr 129:942-948, 1999
33. Field FJ, Born E, Mathur SN: Fatty acid flux suppresses fatty acid synthesis in hamster intestine independently of sterol regulatory element-binding protein-1 expression. J Lipid Res 44:1199-1208, 2003